Streptococcal necrotising fasciitis from diverse strains of Streptococcus pyogenes in tropical northern Australia: Case series and comparison with the literature

BMC Infectious Diseases

Volumn 4, Issue , 2004, Pages

  Hassell, Marilyn ^a   Fagan, Peter ^b   Carson, Phillip ^a   Currie, Bart J ^a,b  

^a FLINDERS UNIVERSITY   (Australia)

^b MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; CLINDAMYCIN; FLUCLOXACILLIN; GENTAMICIN; IMMUNOGLOBULIN; MEROPENEM; METRONIDAZOLE; OXYGEN; PENICILLIN G; TOBRAMYCIN; VIRULENCE FACTOR;

ABORIGINE; ADULT; ARTICLE; AUSTRALIA; BACTEREMIA; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CASE STUDY; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CLONAL VARIATION; CLUSTER ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FATALITY; FEMALE; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; INCIDENCE; LABORATORY TEST; LEUKOCYTOSIS; LYMPHOCYTOPENIA; MALE; MEDICAL LITERATURE; MORTALITY; NECROTIZING FASCIITIS; NONHUMAN; POPULATION RESEARCH; PUBLICATION; SEQUENCE ANALYSIS; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PYOGENES; TOXIC SHOCK SYNDROME; TROPICS; CLASSIFICATION; COMPARATIVE STUDY; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; PATHOPHYSIOLOGY;

ADULT; AUSTRALIA; FASCIITIS, NECROTIZING; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES;

EID: 25444442634     PISSN: 14712334     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-4-60     Document Type: Article

References (51)

1. Guiliano A, Lewis F, Hadley K, Blaisdell FW: Bacteriology of necrotizing fasciitis. Am J Surg 1977, 134:52-57.
2. Meleney FL: Hemolytic streptococcus gangrene. Arch Surg 1924, 9:317-364.
3. Stevens DL: The flesh-eating bacterium: what's next? J Infect Dis 1999, 179(Suppl 2):S366-374.
4. Chelsom J, Halstensen A, Haga T, Hoiby EA: Necrotising fasciitis due to group A streptococci in western Norway: incidence and clinical features. Lancet 1994, 344:1111-1115.
5. Kaul R, McGeer A, Low DE, Green K, Schwartz B: Population-based surveillance for Group A streptococcal necrotizing fasciitis: clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases. Am J Med 1997, 103:18-24.
6. Haywood C, McGeer A, Low D: Clinical experience with 20 cases of Group A streptococcus necrotizing fasciitis and myonecrosis: 1995 to 1997. Plast Reconst Surg 1999, 103:1567-1573.
7. Cleary PP, Kaplan EL, Handley JP, Wlazlo A, Kim MH, Hauser AR, Schlievert PM: Clonal basis for resurgence of serious Streptococcus pyogenes disease in the 1980's. Lancet 1992, 339:518-21.
8. Carapetis JR, Currie BJ, Kaplan EL: Epidemiology and prevention of Group A streptococcal infections: acute respiratory tract infections, skin infections, and their sequelae at the close of the Twentieth Century. Clin Infect Dis 1999, 28:205-210.
9. Carapetis JR, Walker AM, Hibble M, Sriprakash KS, Currie BJ: Clinical and epidemiological features of group A streptococcal bacteraemia in a region with hyperendemic superficial streptococcal infection. Epidemiol Infect 1999, 122:59-65.
10. Trewin D: Population Distribution: Aboriginal and Torres Strait Islander Australians 2001-2002. Australian Bureau of Statistics, Canberra, Australia.
11. The Working Group on Severe Streptococcal Infections: Defining the group A streptococcal toxic shock syndrome: Rationale and consensus definition. JAMA 1993, 269:390-391.
12. Beall B, Facklam R, Thompson T: Sequencing emm-specific PCR products for routine and accurate typing of group A streptococci. J Clin Microbiol 1996, 34:953-958.
13. Streptococcus pyogenes emm sequence database [http://www.cdc.gov/ncidod/biotech/strep/strepblast.htm]
14. Gracey M, Williams P, Smith P: Aboriginal Deaths in Western Australia: 1985-89 and 1990-94. Aust N Z J Public Health 2000, 24:145-152.
15. Cunningham J, Condon JR: Premature mortality in aboriginal adults in the Northern Territory, 1979-1991. Med J Aust 1996, 165:309-312.
16. Sellers B, Woods M, Morris S, Saffle J: Necrotizing group A streptococcal infections associated with streptococcal toxic shock syndrome. Am J Surg 1996, 172:523-528.
17. Simonart T, Simonart JM, Derdelinckx I, De Dobbeleer G, Verleysen A, Verraes S, de Maubeuge J, Van Vooren JP, Naeyaert JM, de la Brassine M, Peetermans WE, Heenen M: Value of standard laboratory tests for the early recognition of group A β-haemolytic streptococcal necrotizing fasciitis. Clin Infect Dis 2001, 32:e9-12.
18. Wall DB, Klein SR, Black S, de Virgilio C: A simple model to help distinguish necrotizing fasciitis from nonnecrotizing soft tissue infection. J Am Coll Surg 2000, 191:227-231.
19. Sudarsky L, Laschinger J, Coppa G, Spencer F: Improved results from a standardized approach in treating patients with necrotizing fasciitis. Ann Surg 1987, 206:661-665.
20. Majeski J, Alexander J: Early diagnosis, nutritional support and immediate extensive debridement improve survival in necrotizing fasciitis. Am J Surg 1983, 145:784-787.
21. Writing Group for Therapeutic Guidelines: Antibiotic Therapeutic Guidelines: Antibiotic 12th edition. Melbourne: Therapeutic Guidelines Ltd; 2003.
22. Gilbert D, Moellering R, Sande M: The Sanford Guide to Antimicrobial Therapy 32nd edition. Hyde Park, VT: Antimicrobial Therapy Inc; 2002.
23. Adams EM, Gudmundsson S, Yocum DE, Haselby RC, Craig WA, Sundstrom WR: Streptococcal myositis. Arch Int Med 1985, 145:1020-1023.
24. Eagle H: Experimental approach to the problem of treatment failure with penicillin. I. Group A streptococcal infection in mice. Am J Med 1952, 13:389-399.
25. Stevens DL, Yan S, Bryant AE: Penicillin binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect. J Infect Dis 1993, 167:1401-1405.
26. Stevens DL, Bryant-Gibbons AE, Bergstrom R, Winn V: The Eagle effect revisited: Efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis 1988, 158:23-28.
27. Stevens DL, Bryant AE, Hackett SP: Antibiotic effects on bacterial viability, toxin production, and host response. Clin Infect Dis 1995, 20(Suppl 2):S154-157.
28. Zimbelman J, Palmer A, Todd J: Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr Infect Dis J 1999, 18:1096-1100.
29. Mulla ZD, Leaverton PE, Wiersma ST: Invasive group A streptococcal infections in Florida. South Med J 2003, 96:968-973.
30. O'Brien CD, Manaker S: Hyperbaric oxygen therapy. In: Up To-Date? Version 11.1. UpToDate, Wellesley, MA 2003.
31. Clark LA, Moon RE: Hyperbaric oxygen in the treatment of life-threatening soft-tissue infections. Respir Care Clin N Am 1999, 5:203-219.
32. Zamboni WA, Mazolewski PJ, Erdmann D, Bergman BA, Hussman J, Cooper MD, Smoot EC, Russell RC: Evaluation of penicillin and hyperbaric oxygen in the treatment of streptococcal myositis. Ann Plast Surg 1997, 39:131-136.
33. Riseman JA, Zamboni WA, Curtis A, Graham DR, Konrad HR, Ross DS: Hyperbaric oxygen therapy for necrotizing fasciitis reduces mortality and the need for debridements. Surgery 1990, 108:847-850.
34. Shupak A, Shoshani O, Goldenberg I, Barzilai A, Moskuna R, Bursztein S: Necrotizing fasciitis: an indication for hyperbaric oxygen therapy? Surgery 1995, 118:873-878.
35. Norrby-Teglund A, Stevens DL: Novel therapies in streptococcal toxic shock syndrome: attenuation of virulence factor expression and modulation of the host response. Curr Opin Infect Dis 1998, 11:285-291.
36. Watanabe-Ohnishi R, Low D, McGeer A, Stevens DL, Schlievert PM, Newton D, Schwartz B, Kreiswirth B, Kotb M: Selective depletion of Vβ-bearing T cells in patients with severe invasive group A streptococcal infections and streptococcal toxic shock syndrome. Ontario Streptococcal Study Project. J Infect Dis 1995, 171:74-84.
37. Holm SE, Norrby A, Bergholm A, Norgren M: Aspects of pathogenesis of serious group A streptococcal infections in Sweden, 1988-1989. J Infect Dis 1992, 166:31-37.
38. Norrby-Teglund A, Kaul R, Low DE, McGeer A, Newton DW, Andersson J, Andersson U, Kotb M: Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production. J Immunol 1996, 156:3057-3064.
39. Norrby-Teglund A, Thulin P, Gan BS, Kotb M, McGeer A, Andersson J, Low DE: Evidence for superantigen involvement in severe group A streptococcal tissue infections. J Infect Dis 2001, 184:853-860.
40. Darenberg J, Ihendyane N, Sjolin J, Aufwerber E, Haidl S, Follin P, Andersson J, Norrby-Teglund A, StreptIg Study Group: Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003, 37:333-340.
41. Barry W, Hudgins L, Donta S, Pesanti E: Intravenous immunoglobulin therapy for toxic shock syndrome. JAMA 1992, 267:3315-3316.
42. Yong JM: Necrotizing fasciitis. Lancet 1994, 343:1427.
43. Stevens DL: Rationale for the use of intravenous gamma globulin in the treatment of streptococcal toxic shock syndrome. Clin Infect Dis 1998, 26:639-641.
44. Martin DR, Single LA: Molecular epidemiology of group A streptococcus M type 1 infections. J Infect Dis 1993, 167:1112-1117.
45. Seppala H, Vuopio-Varkila J, Osterblad M, Jahkola M, Rummukainen M, Holm SE, Huovinen P: Evaluation of methods for epidemiologic typing of group A streptococci. J Infect Dis 1994, 169:519-525.
46. Musser JM, Kapur V, Szeto J, Pan X, Swanson DS, Martin DR: Genetic diversity and relationships among Streptococcus pyogenes strains expressing serotype M1 protein: Recent intercontinental spread of a subclone causing episodes of invasive disease. Infect Immun 1995, 63:994-1003.
47. Descheemaeker P, Van Loock F, Hauchecorne M, Vandamme P, Goossens H: Molecular characterisation of group A streptococci from invasive and non-invasive disease episodes in Belgium during 1993-1994. J Med Microbiol 2000, 49:467-471.
48. Vlaminckx BJ, Mascini EM, Schellekens J, Schouls LM, Paauw A, Fluit AC, Novak R, Verhoef J, Schmitz FJ: Site-specific manifestations of invasive group A streptococcal disease: type distribution and corresponding patterns of virulence determinants. J Clin Microbiol 2003, 41:4941-4949.
49. Chatellier S, Ihendyane N, Kansal RG, Khambaty F, Basma H, Norrby-Teglund A, Low DE, McGeer A, Kotb M: Genetic relatedness and superantigen expression in group A streptococcus serotype M1 isolates from patients with severe and nonsevere invasive diseases. Infect Immun 2000, 68:3523-3534.
50. Chaussee MS, Liu J, Stevens DL, Ferretti JJ: Genetic and phenotypic diversity among isolates of Streptococcus pyogenes from invasive infections. J Infect Dis 1996, 173:901-908.
51. Moses AE, Hidalgo-Grass C, Dan-Goor M, Jaffe J, Shetzigovsky I, Ravins M, Korenman Z, Cohen-Poradosu R, Nir-Paz R: emm typing of M nontypeable invasive group A streptococcal isolates in Israel. J Clin Microbiol 2003, 41:4655-4659.